Zacks: Analysts Anticipate Achillion Pharmaceuticals, Inc. (ACHN) to Announce -$0.14 EPS
Analysts forecast that Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) will announce earnings of ($0.14) per share for the current quarter, Zacks reports. Zero analysts have issued estimates for Achillion Pharmaceuticals’ earnings, with the lowest EPS estimate coming in at ($0.14) and the highest estimate coming in at ($0.13). Achillion Pharmaceuticals also reported earnings per share of ($0.14) during the same quarter last year. The business is scheduled to report its next quarterly earnings results on Wednesday, November 7th.
According to Zacks, analysts expect that Achillion Pharmaceuticals will report full year earnings of ($0.52) per share for the current fiscal year, with EPS estimates ranging from ($0.55) to ($0.50). For the next fiscal year, analysts forecast that the business will post earnings of ($0.61) per share, with EPS estimates ranging from ($0.62) to ($0.60). Zacks Investment Research’s earnings per share averages are an average based on a survey of sell-side analysts that that provide coverage for Achillion Pharmaceuticals.
Achillion Pharmaceuticals (NASDAQ:ACHN) last released its quarterly earnings results on Wednesday, August 8th. The biopharmaceutical company reported ($0.12) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.13) by $0.01.
ACHN traded up $0.23 during trading hours on Friday, reaching $3.76. 117,205 shares of the stock traded hands, compared to its average volume of 1,266,118. The firm has a market cap of $486.44 million, a price-to-earnings ratio of -5.69 and a beta of 1.03. Achillion Pharmaceuticals has a fifty-two week low of $2.33 and a fifty-two week high of $4.82.
Hedge funds have recently made changes to their positions in the business. Acadian Asset Management LLC acquired a new position in Achillion Pharmaceuticals during the 2nd quarter worth $135,000. Cubist Systematic Strategies LLC acquired a new position in Achillion Pharmaceuticals during the 2nd quarter worth $147,000. BlueMountain Capital Management LLC acquired a new position in Achillion Pharmaceuticals during the 2nd quarter worth $159,000. Element Capital Management LLC acquired a new position in Achillion Pharmaceuticals during the 1st quarter worth $163,000. Finally, New York State Common Retirement Fund grew its holdings in Achillion Pharmaceuticals by 24.1% during the 1st quarter. New York State Common Retirement Fund now owns 146,800 shares of the biopharmaceutical company’s stock worth $545,000 after acquiring an additional 28,500 shares in the last quarter. 78.36% of the stock is owned by institutional investors.
Achillion Pharmaceuticals Company Profile
Achillion Pharmaceuticals, Inc, a biopharmaceutical company, discovers, develops, and commercializes small molecule drug therapies for immune system disorders in the United States. Its lead drug candidate includes ACH-4471, an inhibitor of factor D that is Phase II clinical trials for patients with paroxysmal nocturnal hemoglobinuria and C3 glomerulopathy.
Recommended Story: Technical Analysis of Stocks, How Can It Help
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Achillion Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Achillion Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.